A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

BACKGROUND: The epidermal growth factor receptor (EGFR) is a validated target in squamous cell carcinoma of the head and neck but in patients with recurrent or metastatic disease, EGFR targeting agents have displayed modest efficacy. Vascular endothelial growth factor (VEGF) mediated angiogenesis ha...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Cohen, Ezra EW, Davis, Darren W., Karrison, Theodore G, Seiwert, Tanguy Y., Wong, Stuart J., Nattam, Sreenivasa, Kozloff, Mark F., Clark, Joseph I., Yan, Duen-Hwa, Liu, Wen, Pierce, Carolyn, Dancey, Janet E, Stenson, Kerstin, Blair, Elizabeth, Dekker, Allison, Vokes, Everett E
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768532/
https://ncbi.nlm.nih.gov/pubmed/19201650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(09)70002-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items